Superworth

uniQure price to book ratio QURE

Market value divided by the book value of the company's net assets, since 2017.

Today, Oct 23, 2026
4.8×
10-year median
6.0×
Against its 10-year history
42nd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.8× to 41.8×
Peer median
2.8×

uniQure's price to book ratio is 4.8× as of Oct 23, 2026.

That is below its ten-year median of 6.0×, close to the middle of its last ten years.

Over that time it ranged from 0.8× in Oct 2023 to 41.8× in Mar 2018.

The median for 10 large drugmakers of a similar size is 2.8×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.8×4.3×20.1×
20256.8×5.3×28.1×
202415.3×1.0×15.3×
20231.2×0.8×2.6×
20222.5×1.2×3.0×
20211.6×1.6×8.0×
20207.1×5.9×10.1×
20199.0×5.2×19.8×
20185.0×4.4×41.8×
201730.8×2.0×30.8×

Against its peers

Companies in Drug Manufacturers - General nearest uniQure's size, closest first, today.

CompanyPrice to book ratio
QUREuniQure4.8×
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
ANIPANI Pharmaceuticals2.8×
OMEROmerosn/m
HRMYHarmony Biosciences2.1×
AMPHAmphastar Pharmaceuticals1.4×
PBHPrestige Consumer Healthcare1.2×
NRIXNurix Therapeutics2.9×
ABUSArbutus Biopharma3.2×
Peer median2.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on uniQure

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.